Hypopara Life — Bari's Hypoparathyroidism Blog
Honest stories, real experiences, and the unfiltered truth about living with hypoparathyroidism. Because you are not alone on this journey.
"I write because I have to. Because if even one person reads my story and feels less alone, then every painful word was worth it. This blog is my heart on a page — raw, real, and unapologetically honest."
— Bari
What Is Immunogenicity — And Why Does It Matter for Eneboparatide?
When the CALYPSO results came out, one word kept appearing in the coverage: immunogenicity. Most patients I know had never heard it before. I want to break it down in plain language, because I think our community deserves to understand exactly what happened in this trial — and what it means for the future of eneboparatide.
BridgeBio Filed the NDA. This Is What It Means for Our Community.
Today, BridgeBio Pharma submitted a New Drug Application to the FDA for encaleret for autosomal dominant hypocalcemia type 1 (ADH1). I have been following this drug for years. I have read every press release, every abstract, every trial update. And today, I am sitting here with a full heart. This is not a small moment. This is the moment.
CALYPSO Results Are In: 31.1% of Patients Achieved Supplement Independence with Eneboparatide
Today at the European Congress of Endocrinology in Prague, AstraZeneca and Alexion presented the full results of the CALYPSO Phase III trial of eneboparatide. 31.1% of patients achieved normalised serum calcium and independence from active vitamin D and oral calcium supplements at week 24 -- compared to just 5.9% in the placebo group. That is a statistically significant result (p=0.0001). And it means something real to our community. I want to be honest: 31.1% is not 100%. There are immunogenicity findings that affected some patients, and the full picture is still being studied. But 31.1% is a door opening. It is proof that a PTH receptor agonist can restore mineral homeostasis in a meaningful number of patients. Urinary calcium was also normalised in 56.6% of hypercalciuric patients -- a secondary endpoint that matters enormously for kidney health. The drug was well tolerated over 52 weeks. Every percentage point in that 31.1% represents a real person who got their calcium under control without daily supplements. That is someone who got a piece of their life back. I am watching eneboparatide very closely. Regulatory submissions are anticipated in 2026. If approved, it would be the second PTH replacement therapy available in the US -- and more options always mean more hope. Anything is possible.
It's OK, Hypopara, Vienna Waits for Me
I grew up a few miles from Billy Joel, so his music is part of my DNA. In 2024, while my mom was fighting for her life in the ICU, I would sit beside her and play songs from my Life Playlist — including "Vienna." I talked to her not knowing if she could hear me. I made promises: if she got back on the golf course, I would take lessons and play with her. I promised a mommy-daughter trip. And then one miraculous day, Mom woke up. A few days later she told me about a "strange dream" — and I realized she had heard every word. When I asked her where she wanted to go on our trip, she said: Vienna. Of all the places in the world. This Mother's Day, I am celebrating her comeback, her strength, and the reminder that life is fragile and beautiful. Vienna is waiting for me — and I will get there. Anything is possible.
Entera's EB613 Is Moving to Phase 3 — And That Means an Oral PTH Option May Be Coming
I have been watching Entera Bio for a while now, and today's news gave me real reason to feel hopeful. Entera just announced that their single-tablet formulation of EB613 — an oral PTH(1–34) — is advancing into Phase 3 as the lead candidate, following a successful Phase 1 PK and safety bridging study completed in January 2026. That study compared the single tablet to both the multi-tablet formulation and to Forteo® (teriparatide, the injectable PTH we all know). Think about what that means for our community: a once-daily oral tablet that could replace injections. For those of us who have been on Yorvipath or other injectables, the idea of swallowing a pill instead of giving yourself a shot every day is not a small thing. It is a life-quality thing. Entera also submitted proof-of-concept data for EB612 in hypoparathyroidism and EB618 in metabolic conditions to ENDO2026 and ASBMR — so they are building a real pipeline, not just a single bet. We are not there yet. Phase 3 takes time. But the direction is right, the science is moving, and the fact that multiple companies are now racing toward better treatments for hypoparathyroidism tells me that our advocacy is working. Keep sharing your story. Keep showing up. Anything is possible.
Two Treatments on the Horizon: My Reaction to the BridgeBio & MBX Updates
For years, those of us living with hypoparathyroidism and ADH1 have been told to be patient. Today, I have never been more hopeful. BridgeBio just announced they plan to submit an NDA to the FDA for encaleret in the first half of 2026 — with a U.S. launch anticipated in early 2027. And MBX Biosciences is advancing canvuparatide into Phase 3 after a successful End-of-Phase 2 FDA meeting. Two potential new treatments. Two companies fighting for us. The CALIBRATE Phase 3 primary results will be presented at ECE on May 12 — and I will be watching. This is what advocacy looks like when it works. Anything is possible.
Why I Jumped Out of a Plane with Hypoparathyroidism
They said I couldn't. They said it was too risky. But living with hypopara has taught me one thing — if you wait for the 'perfect' day, you'll never live. So I jumped. And it was the most freeing moment of my life.
The Day My Calcium Crashed and Everything Changed
One moment I was fine. The next, my body was shutting down. A life-altering calcium crash sent me to the ER and changed the trajectory of my advocacy forever. This is that story.
From Patient #1 to FDA Approval: The Yorvipath Story
Being the first patient in the TransCon PTH clinical trial was terrifying and exhilarating. Years later, watching Yorvipath receive FDA approval was one of the proudest moments of my life. Here's what that journey looked like from the inside.
What Brain Fog Really Feels Like
It's not just 'being forgetful.' Brain fog with hypopara is like trying to think through a wall of cotton. Words disappear mid-sentence. You forget why you walked into a room. You read the same paragraph five times. Here's what I wish people understood.
A Letter to My Children: Why Mommy Fights
Drew and Harrison — you are my reason. Every column I write, every speech I give, every day I push through the pain — it's for you. And for every parent with hypopara who wants to be there for their kids.
Athletes and Hypopara: We Are All Warriors
I draw parallels between professional athletes and hypopara patients. We both fight through pain, push past limits, and never give up. Every good day is a win. Every setback is a setup for a comeback.
The Invisible Illness: Why Nobody Believes You're Sick
You look fine. You don't look sick. Have you tried yoga? The comments never stop. Living with an invisible illness means constantly proving that your pain is real. Here's how I handle it — and how you can too.
Finding My Voice: How Writing Saved My Life
When I started writing for HypoParathyroidism News, I had no idea it would become my lifeline. Putting my story into words helped me process the pain, connect with others, and find purpose in the struggle.
Read My Published Columns
My official column "Brave Butterfly" is published on HypoParathyroidism News. Read all my published columns there.
Disclaimer: The content on this blog reflects personal experiences and opinions and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions regarding your medical condition.